Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer

Open access
Paz-Ares, L, Ross, H, O'Brien, M, Riviere, A, Gatzemeier, U, Von Pawel, J, Kaukel, E, Freitag, L, Digel, W, Bischoff, H, García-Campelo, R, Iannotti, N, Reiterer, P, Bover, I, Prendiville, J, Eisenfeld, A J, Oldham, F B, Bandstra, B, Singer, J W, Bonomi, P·2008·British Journal of Cancer

Abstract

Paclitaxel poliglumex (PPX), a macromolecule drug conjugate linking paclitaxel to polyglutamic acid, reduces systemic exposure to peak concentrations of free paclitaxel. Patients with non-small-cell lung cancer (NSCLC) who had received one prior platinum-based chemotherapy received 175 or 210 mg m(-2) PPX or 75 mg m(-2) docetaxel. The study enrolled 849 previously treated NSCLC patients with advanced disease. Median survival (6.9 months in both arms, hazard ratio=1.09, P=0.257), 1-year survival (PPX=25%, docetaxel=29%, P=0.134), and time to progression (PPX=2 months, docetaxel=2.6 months, P=0.075) were similar between treatment arms. Paclitaxel poliglumex was associated with significantly less grade 3 or 4 neutropenia (P<0.001) and febrile neutropenia (P=0.006). Grade 3 or 4 neuropathy (P<0.001) was more common in the PPX arm. Patients receiving PPX had less alopecia and did not receive routine premedications. More patients discontinued due to adverse events in the PPX arm compared to the docetaxel arm (34 vs 16%, P<0.001). Paclitaxel poliglumex and docetaxel produced similar survival results but had different toxicity profiles. Compared with docetaxel, PPX had less febrile neutropenia and less alopecia, shorter infusion times, and elimination of routine use of medications to prevent hypersensitivity reactions. Paclitaxel poliglumex at a dose of 210 mg m(-2) resulted in increased neurotoxicity compared with docetaxel.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6604372

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 171

Metadata

Authors
Paz-Ares, L., Ross, H., O'Brien, M., Riviere, A., Gatzemeier, U., Von Pawel, J., Kaukel, E., Freitag, L., Digel, W., Bischoff, H., García-Campelo, R., Iannotti, N., Reiterer, P., Bover, I., Prendiville, J., Eisenfeld, A. J., Oldham, F. B., Bandstra, B., Singer, J. W., & Bonomi, P.
Venue
British Journal of Cancer
Published
2008-05
Volume
98
Issue
10
Pages
1608-1613
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2056647735
Cited by
171
References
2
FWCI
10.57
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. https://app.cochat.ai/papers/10.1038/sj.bjc.6604372
The paper
Paz-Ares, L., Ross, H., O'Brien, M., Riviere, A., Gatzemeier, U., Von Pawel, J., Kaukel, E., Freitag, L., Digel, W., Bischoff, H., García-Campelo, R., Iannotti, N., Reiterer, P., Bover, I., Prendiville, J., Eisenfeld, A. J., Oldham, F. B., Bandstra, B., Singer, J. W., & Bonomi, P. (2008). Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6604372

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.